Shanghai Rendu Biotechnology Co., Ltd. (SHA:688193)
China
· Delayed Price · Currency is CNY 51.28
-1.53 (-2.90%)
At close: Mar 9, 2026
SHA:688193 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 162.06 | 175.91 | 162.76 | 293.94 | 286.13 | Upgrade
|
| Other Revenue | - | 1.44 | 1.65 | 9.91 | 6.18 | Upgrade
|
| Revenue | 162.06 | 177.35 | 164.41 | 303.85 | 292.31 | Upgrade
|
| Revenue Growth (YoY) | -8.62% | 7.87% | -45.89% | 3.95% | 16.97% | Upgrade
|
| Cost of Revenue | - | 39.1 | 32.09 | 106.11 | 74.38 | Upgrade
|
| Gross Profit | 162.06 | 138.25 | 132.32 | 197.74 | 217.93 | Upgrade
|
| Selling, General & Admin | - | 119.98 | 118.1 | 155.04 | 127.4 | Upgrade
|
| Research & Development | - | 38.45 | 40.54 | 33.89 | 26.12 | Upgrade
|
| Other Operating Expenses | 152.32 | -2.03 | -0.69 | 0.86 | 0.83 | Upgrade
|
| Operating Expenses | 152.32 | 173.23 | 158.55 | 192.72 | 155.35 | Upgrade
|
| Operating Income | 9.75 | -34.98 | -26.23 | 5.02 | 62.58 | Upgrade
|
| Interest Expense | - | -0.29 | -0.43 | -0.36 | -0.26 | Upgrade
|
| Interest & Investment Income | - | 17.76 | 15.65 | 12.57 | 3.21 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.01 | -0.12 | 0.56 | -0.2 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.21 | -0.3 | -0.06 | 0.13 | -0.15 | Upgrade
|
| EBT Excluding Unusual Items | 9.54 | -17.83 | -11.19 | 17.93 | 65.18 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -0.24 | 0.66 | 0.98 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.14 | -0.05 | 0.14 | 0.76 | Upgrade
|
| Asset Writedown | - | -0.83 | -0.34 | -1.19 | -0.38 | Upgrade
|
| Other Unusual Items | - | 3.54 | 15.68 | 8.82 | 6.89 | Upgrade
|
| Pretax Income | 9.54 | -15.22 | 4.76 | 26.68 | 72.44 | Upgrade
|
| Income Tax Expense | 0.03 | -7.41 | -3.5 | 3.35 | 7.82 | Upgrade
|
| Net Income | 9.51 | -7.81 | 8.26 | 23.33 | 64.62 | Upgrade
|
| Net Income to Common | 9.51 | -7.81 | 8.26 | 23.33 | 64.62 | Upgrade
|
| Net Income Growth | - | - | -64.60% | -63.89% | 5.28% | Upgrade
|
| Shares Outstanding (Basic) | 40 | 39 | 39 | 38 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 40 | 39 | 39 | 38 | 30 | Upgrade
|
| Shares Change (YoY) | 1.43% | -0.68% | 2.83% | 26.08% | 0.95% | Upgrade
|
| EPS (Basic) | 0.24 | -0.20 | 0.21 | 0.62 | 2.15 | Upgrade
|
| EPS (Diluted) | 0.24 | -0.20 | 0.21 | 0.61 | 2.13 | Upgrade
|
| EPS Growth | - | - | -65.57% | -71.36% | 4.41% | Upgrade
|
| Free Cash Flow | - | 13.86 | -3.2 | -25.31 | 27.97 | Upgrade
|
| Free Cash Flow Per Share | - | 0.35 | -0.08 | -0.66 | 0.92 | Upgrade
|
| Dividend Per Share | - | 0.200 | 0.200 | 0.125 | - | Upgrade
|
| Dividend Growth | - | - | 60.00% | - | - | Upgrade
|
| Gross Margin | 100.00% | 77.95% | 80.48% | 65.08% | 74.56% | Upgrade
|
| Operating Margin | 6.01% | -19.73% | -15.95% | 1.65% | 21.41% | Upgrade
|
| Profit Margin | 5.87% | -4.41% | 5.02% | 7.68% | 22.11% | Upgrade
|
| Free Cash Flow Margin | - | 7.82% | -1.94% | -8.33% | 9.57% | Upgrade
|
| EBITDA | 23.87 | -20.86 | -13.43 | 17.42 | 70.93 | Upgrade
|
| EBITDA Margin | 14.73% | -11.76% | -8.17% | 5.73% | 24.27% | Upgrade
|
| D&A For EBITDA | 14.12 | 14.12 | 12.8 | 12.4 | 8.35 | Upgrade
|
| EBIT | 9.75 | -34.98 | -26.23 | 5.02 | 62.58 | Upgrade
|
| EBIT Margin | 6.01% | -19.73% | -15.95% | 1.65% | 21.41% | Upgrade
|
| Effective Tax Rate | 0.34% | - | - | 12.56% | 10.80% | Upgrade
|
| Revenue as Reported | - | 177.35 | 164.41 | 303.85 | 292.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.